Home Menu

Site Navigation



NeuroTalk Support Groups > > >

Evaluating Risk versus Benefit of Drugs for MS

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 10-01-2006, 10:55 PM #9
Harry Z Harry Z is offline
Member
  
Join Date: Sep 2006
Location: London, Canada
Posts: 241
15 yr Member
Harry Z Harry Z is offline
Member
 
Join Date: Sep 2006
Location: London, Canada
Posts: 241
15 yr Member
Default
Quote:
So, if a drug company, (lets take Biogen as an example), says that there are 47% less attacks on Tysabri, this article points out how that tells you very little about the benefit of Tysabri. It can mask the real data which might show that it is far less effective than that.
On the "old" BT forum, Mark looked at the CRAB stats and compared them with what Biogen has been touting with Tysabri. He came up with a number that said Tysabri was only about 12% more effective than the CRABs.

Now after reading this article comparing relative and absolute numbers, does anyone really think that Biogen is being truthful about the efficacy of Tysabri?

Harry
Harry Z is offline   Reply With QuoteReply With Quote
 

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


All times are GMT -5. The time now is 03:27 PM.


Powered by vBulletin • Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise (Lite) - vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home